Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer - A Southwest Oncology Group study

Stephen K. Williamson, John Crowley, Robert B. Livingston, Geoffrey Weiss

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Nineteen eligible patients with recurrent small cell lung cancer were treated with a 120 hour continuous infusion of 6-thioquanine at a starting dose of 35 mg/m2/day. There were no responses in these 19 patients. Toxicity was acceptable with the primary toxicity being hematologic. Based on this trial, 6-thioquanine is not felt to have significant antitumor activity in this patient population.

Original languageEnglish (US)
Pages (from-to)81-83
Number of pages3
JournalInvestigational New Drugs
Volume11
Issue number1
DOIs
StatePublished - Feb 1993

Keywords

  • 6-thioguanine
  • chemotherapy
  • phase II
  • small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer - A Southwest Oncology Group study'. Together they form a unique fingerprint.

Cite this